Rinucumab - Misplaced Pages

Monoclonal antibody Pharmaceutical compound

Rinucumab
Monoclonal antibody
Type	?
Source	Human
Target	platelet-derived growth factor receptor beta
Clinical data
Other names	REGN2176
ATC code	none
Identifiers
CAS Number	1569263-06-4
ChemSpider	none
UNII	10E3O6YI4W
Chemical and physical data
Formula	C₆₄₇₂H₉₉₇₄N₁₇₁₀O₂₀₂₂S₃₈
Molar mass	145309.21 g·mol

Rinucumab (REGN2176) is a monoclonal antibody designed for the treatment of neovascular age-related macular degeneration.

This drug was developed by Regeneron Pharmaceuticals, Inc.

References

"Rinucumab" (PDF). Statement On A Nonproprietary Name Adopted By The USAN Council. American Medical Association.
Hussain RM, Ciulla TA (September 2017). "Emerging vascular endothelial growth factor antagonists to treat neovascular age-related macular degeneration". Expert Opinion on Emerging Drugs. 22 (3): 235–246. doi:10.1080/14728214.2017.1362390. PMID 28756707. S2CID 3505145.

This monoclonal antibody–related article is a stub. You can help Misplaced Pages by expanding it.

Monoclonals for bone, musculoskeletal, circulatory, and neurologic systems

Human	Burosumab Denosumab
Humanized	Blosozumab Romosozumab

Human	Stamulumab

Human	Abelacimab Alirocumab Ascrinvacumab Bentracimab Enoticumab Evinacumab Evolocumab Icrucumab Inclacumab Marstacimab Nesvacumab Orticumab Ramucirumab Rinucumab
Mouse	Biciromab Imciromab
Chimeric	Abciximab Volociximab
Humanized	Alacizumab pegol Bevacizumab/Ranibizumab Bococizumab Brolucizumab Caplacizumab Concizumab Demcizumab Emicizumab Etaracizumab Faricimab Idarucizumab Ralpancizumab Tadocizumab Vanucizumab

Human	Anti-amyloid drugs Aducanumab Donanemab Gantenerumab Lecanemab Erenumab Fasinumab Fulranumab Opicinumab
Humanized	Bapineuzumab Crenezumab Eptinezumab Fremanezumab Galcanezumab Ozanezumab Ponezumab Refanezumab Semorinemab Solanezumab Tanezumab

Humanized	Ranibizumab

Human	Bimagrumab Trevogrumab
Humanized	Domagrozumab Landogrozumab